Safety and Efficacy of MBF-118 in Patients with Crohn Disease
Status:
COMPLETED
Trial end date:
2024-09-10
Target enrollment:
Participant gender:
Summary
This is a Phase IIa (proof of concept), single center clinical trial to evaluate the safety and efficacy of daily MBF-118 oral treatment during 28 days in Crohn's disease patients on top of standard of care.